Bocio intratorácico gigante de presentación atípica

Hemangioma cavernoso esternal y reconstrucción de la pared torácica anterior

No abstract

respectively. Six patients reported 10 treatment-related adverse events (TRAEs) (6 grade 1; 2 grade 2; 2 grade 3). Two grade 3 TRAEs were anemia in a patient with baseline grade 2 anemia and diarrhea that lasted 2 days in another patient. 10 patients were evaluable for tumor response: 5 patients had a partial response (2 of which were confirmed), 4 had stable disease, and 1 had progressive disease (PD). Of all 13 patients enrolled, 11 remained on study, and 2 discontinued due to PD. Conclusion: AMG 510 is well tolerated at all 4 dose levels and showed antitumor activity in patients with advanced KRAS G12C mutant NSCLC. Enrollment is ongoing (ClinicalTrials.gov identifier: NCT03600883).

Paratiroides ectópica en Timo